Clinical Trials Logo
  1. Home
  2. Other
  3. NCT03177499

Virtual Imaging-based Early Portal Pressure Gradient (vePPG) (CHESS1702) — vePPG  

Hypertension, Portal Clinical Trial

Official title:
Virtual Imaging-based Early Portal Pressure Gradient (vePPG) After Placement of Transjugular Intrahepatic Portosystemic Shunts in Patients With Portal Hypertension

Clinical Trial Summary

Portal pressure gradient (PPG) above 12 mmHg after transjugular intrahepatic portosystemic shunt (TIPS) increases the risk of portal hypertension complications. Currently, a PPG reduction <12 mmHg after TIPS is the most consistent threshold associated with almost complete protection from variceal bleeding and ascites. However, the measurement of PPG requires an invasive procedure. A recent study investigated the variations in PPG measurements collected at different time points after placement of TIPS and demonstrated that a time point of at least 24 hours after which PPG values were best maintained (early PPG). It is of great clinical value to propose that an immediate PPG measurement fail to accurately identify the risk of decompensated event. And early PPG would change the decision making for re-intervention or not. However, the repeated invasive examination is extremely difficult to follow in clinical practice worldwide. The prospective multicenter trial aims to assess the diagnostic performance of a virtual imaging-based early portal pressure gradient (vePPG) (investigational technology) from CT angiography and Doppler ultrasound with invasive early PPG measurement as reference. The study participants with portal hypertension will be prospectively recruited at 10 high-volume liver centers in China.

Clinical Trial Description

Portal pressure gradient (PPG) above 12 mmHg after transjugular intrahepatic portosystemic shunt (TIPS) increases the risk of portal hypertension complications. Currently, a PPG reduction <12 mmHg after TIPS is the most consistent threshold associated with almost complete protection from variceal bleeding and ascites. However, the measurement of PPG requires an invasive procedure. A recent study investigated the variations in PPG measurements collected at different time points after placement of TIPS and demonstrated that a time point of at least 24 hours after which PPG values were best maintained (early PPG). It is of great clinical value to propose that an immediate PPG measurement fail to accurately identify the risk of decompensated event. And early PPG would change the decision making for re-intervention or not. However, the repeated invasive examination is extremely difficult to follow in clinical practice worldwide. The prospective multicenter trial aims to assess the diagnostic performance of a virtual imaging-based early portal pressure gradient (vePPG) (investigational technology) from CT angiography and Doppler ultrasound with invasive early PPG measurement as reference. The study participants with portal hypertension will be prospectively recruited at 10 high-volume liver centers (Beijing Shijitan Hospital; 302 Hospital of PLA; Nanfang Hospital, Southern Medical University; The Third Xiangya Hospital of Central South University; Xingtai People's Hospital; Affiliated Traditional Chinese Medicine Hospital, Southwest Medical University; First Affiliated Hospital, Sun Yat-Sen University; Beijing Ditan Hospital; PLA Army General Hospital; Third Affiliated Hospital, Sun Yat-Sen University) in China. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03177499
Study type Interventional
Source Nanfang Hospital of Southern Medical University
Contact
Status Withdrawn
Phase N/A
Start date August 24, 2017
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03713606 - Serum Biomarkers for Portal Hypertension in Cirrhosis (Pan-CHESS1802)
Recruiting NCT02505152 - Percutaneous Transhepatic Intrahepatic Portosystemic Shunt for Treatment of Portal Vein Occlusion With Symptomatic Portal Hypertension After Splenectomy N/A
Recruiting NCT02504034 - Interventional Radiology for the Treatment of Symptomatic Portal Hypertension in Patients With Cavernous Transformation of Portal Vein N/A
Completed NCT02669875 - Serelaxin To Lower Portal Pressure Phase 2
Recruiting NCT04720456 - SHAPE of Portal Hypertension in Children Phase 2
Completed NCT04645550 - Apixaban, Warfarin and Aspirin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy（ESAWAAPT） Phase 4
Recruiting NCT02305914 - Follow-up Study of Complications of Acute Pancreatitis N/A
Completed NCT01095185 - Efficacy of Statin Association With Standard Treatment in Prevention of Recurrent Hemorrhage in Patient With Cirrhosis and Variceal Bleeding Phase 3
Terminated NCT05282121 - A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Phase 2
Completed NCT00004641 - A Study to Prevent Complications of High Blood Pressure Caused by Hepatitis in Patients With Cirrhosis Phase 2
Completed NCT03138915 - Radiomics Signature of Hepatic Venous Pressure Gradient (rHVPG) With CT Angiography (CHESS1701) N/A
Completed NCT03175731 - PPIs and Gastroesophageal Varices in Liver Cirrhosis (PPIs: Proton Pump Inhibitors) Phase 4
Active, not recruiting NCT04315571 - Comparing Ascites Relief In Two Standard Treatments: Large Volume Paracentesis Vs. Early Tips Using Viatorr Controlled Expansion Stents N/A
Completed NCT03459378 - Outcome After TIPS
Recruiting NCT03470389 - Establishment and Assessment of the HVPG Using Biofluid Mechanics (HVPGBFM) N/A
Completed NCT02462967 - Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis Phase 2
Active, not recruiting NCT01097811 - Comparison Between Erythromycin and Neomycin Treatment of Hepatic Encephalopathy N/A
Terminated NCT06082843 - A Study to Test Whether Avenciguat Helps People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) Who Had Bleeding in the Esophagus or Fluid Accumulation in the Belly Phase 2
Recruiting NCT03315767 - Spleen-ARFI-assisted-Portal-Hypertension-Evaluation-Study (SAPHES) N/A
Terminated NCT05161481 - A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live Phase 2